JP2016514091A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016514091A5 JP2016514091A5 JP2015557148A JP2015557148A JP2016514091A5 JP 2016514091 A5 JP2016514091 A5 JP 2016514091A5 JP 2015557148 A JP2015557148 A JP 2015557148A JP 2015557148 A JP2015557148 A JP 2015557148A JP 2016514091 A5 JP2016514091 A5 JP 2016514091A5
- Authority
- JP
- Japan
- Prior art keywords
- mutation
- antibody
- ttr
- item
- native
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000035772 mutation Effects 0.000 claims description 198
- 108010071690 Prealbumin Proteins 0.000 claims description 85
- 102000009190 Transthyretin Human genes 0.000 claims description 85
- 206010002022 amyloidosis Diseases 0.000 claims description 27
- 102200150628 rs151220873 Human genes 0.000 claims description 14
- 230000027455 binding Effects 0.000 claims description 10
- 102220040362 rs141591400 Human genes 0.000 claims description 6
- 238000000159 protein binding assay Methods 0.000 claims description 4
- 206010007509 Cardiac amyloidosis Diseases 0.000 claims description 3
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims description 3
- 208000003295 carpal tunnel syndrome Diseases 0.000 claims description 3
- 208000027121 wild type ATTR amyloidosis Diseases 0.000 claims description 3
- 102220471946 Axin interactor, dorsalization-associated protein_H56R_mutation Human genes 0.000 claims description 2
- 102220600742 Calmodulin-binding transcription activator 1_G53A_mutation Human genes 0.000 claims description 2
- 102220544656 Coagulation factor X_E54G_mutation Human genes 0.000 claims description 2
- 102220520746 Cystatin-C_A25S_mutation Human genes 0.000 claims description 2
- 102220465994 Dihydrofolate reductase 2, mitochondrial_I68M_mutation Human genes 0.000 claims description 2
- 102220465992 Dihydrofolate reductase 2, mitochondrial_Y69H_mutation Human genes 0.000 claims description 2
- 102220476001 Ectodysplasin-A_L55R_mutation Human genes 0.000 claims description 2
- 102220566386 Forkhead box protein L2_I84N_mutation Human genes 0.000 claims description 2
- 102220566385 Forkhead box protein L2_I84S_mutation Human genes 0.000 claims description 2
- 102220616501 Gamma-crystallin D_A36P_mutation Human genes 0.000 claims description 2
- 102220539815 HLA class II histocompatibility antigen, DQ beta 1 chain_Y69I_mutation Human genes 0.000 claims description 2
- 102220585092 Histone H3.Y_A97S_mutation Human genes 0.000 claims description 2
- 102220505281 NADH-ubiquinone oxidoreductase chain 5_I84T_mutation Human genes 0.000 claims description 2
- 102220505300 NADH-ubiquinone oxidoreductase chain 5_V122I_mutation Human genes 0.000 claims description 2
- 102220505315 NADH-ubiquinone oxidoreductase chain 5_V20I_mutation Human genes 0.000 claims description 2
- 102220475913 Oligophrenin-1_E89K_mutation Human genes 0.000 claims description 2
- 102220511395 Proteasome subunit beta type-10_K35T_mutation Human genes 0.000 claims description 2
- 102220467909 Protein Dok-7_V32A_mutation Human genes 0.000 claims description 2
- 102220645376 Sodium- and chloride-dependent betaine transporter_C10R_mutation Human genes 0.000 claims description 2
- 102220494820 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial_F33V_mutation Human genes 0.000 claims description 2
- 102220536557 Transcription factor NF-E4_A45D_mutation Human genes 0.000 claims description 2
- 102220579299 Transthyretin_D38E_mutation Human genes 0.000 claims description 2
- 102220579482 Transthyretin_G67E_mutation Human genes 0.000 claims description 2
- 230000015572 biosynthetic process Effects 0.000 claims description 2
- 102220357373 c.265G>C Human genes 0.000 claims description 2
- 102220414639 c.325G>T Human genes 0.000 claims description 2
- 102220353134 c.68G>A Human genes 0.000 claims description 2
- 239000000178 monomer Substances 0.000 claims description 2
- 102220284214 rs1000821034 Human genes 0.000 claims description 2
- 102200070532 rs104894304 Human genes 0.000 claims description 2
- 102200160559 rs104894505 Human genes 0.000 claims description 2
- 102220004692 rs104894664 Human genes 0.000 claims description 2
- 102200115856 rs104894665 Human genes 0.000 claims description 2
- 102220223852 rs1060502978 Human genes 0.000 claims description 2
- 102220224292 rs1060503516 Human genes 0.000 claims description 2
- 102200061512 rs1064039 Human genes 0.000 claims description 2
- 102200142586 rs11125895 Human genes 0.000 claims description 2
- 102220074162 rs113134544 Human genes 0.000 claims description 2
- 102200114145 rs121434245 Human genes 0.000 claims description 2
- 102200009417 rs121908117 Human genes 0.000 claims description 2
- 102220198133 rs121913385 Human genes 0.000 claims description 2
- 102220054792 rs138065384 Human genes 0.000 claims description 2
- 102220249923 rs1427260162 Human genes 0.000 claims description 2
- 102220142452 rs147257284 Human genes 0.000 claims description 2
- 102220294668 rs1554558878 Human genes 0.000 claims description 2
- 102220242123 rs1556105849 Human genes 0.000 claims description 2
- 102200049725 rs182983506 Human genes 0.000 claims description 2
- 102220039279 rs199473356 Human genes 0.000 claims description 2
- 102220035386 rs200930463 Human genes 0.000 claims description 2
- 102220294624 rs201073751 Human genes 0.000 claims description 2
- 102200112216 rs2273285 Human genes 0.000 claims description 2
- 102200111232 rs28931605 Human genes 0.000 claims description 2
- 102200118257 rs33935983 Human genes 0.000 claims description 2
- 102220005419 rs33976776 Human genes 0.000 claims description 2
- 102220005148 rs34743882 Human genes 0.000 claims description 2
- 102220005545 rs34769782 Human genes 0.000 claims description 2
- 102200082806 rs35303218 Human genes 0.000 claims description 2
- 102200124261 rs374259530 Human genes 0.000 claims description 2
- 102220227599 rs530501230 Human genes 0.000 claims description 2
- 102220162602 rs549769200 Human genes 0.000 claims description 2
- 102200055608 rs61732504 Human genes 0.000 claims description 2
- 102220033838 rs61753984 Human genes 0.000 claims description 2
- 102220056953 rs730880945 Human genes 0.000 claims description 2
- 102220178356 rs769686237 Human genes 0.000 claims description 2
- 102220062179 rs786201468 Human genes 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 description 27
- 230000002744 anti-aggregatory effect Effects 0.000 description 16
- 239000003795 chemical substances by application Substances 0.000 description 15
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 208000024891 symptom Diseases 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 8
- 239000003381 stabilizer Substances 0.000 description 7
- 239000012472 biological sample Substances 0.000 description 6
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005259 measurement Methods 0.000 description 3
- BCMCBBGGLRIHSE-UHFFFAOYSA-N 1,3-benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 2
- 125000000355 1,3-benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- HUPFGZXOMWLGNK-UHFFFAOYSA-N diflunisal Chemical group C1=C(O)C(C(=O)O)=CC(C=2C(=CC(F)=CC=2)F)=C1 HUPFGZXOMWLGNK-UHFFFAOYSA-N 0.000 description 2
- 229960000616 diflunisal Drugs 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- 102000040430 polynucleotide Human genes 0.000 description 2
- 108091033319 polynucleotide Proteins 0.000 description 2
- 239000002157 polynucleotide Substances 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- TXEIIPDJKFWEEC-UHFFFAOYSA-N tafamidis Chemical group O1C2=CC(C(=O)O)=CC=C2N=C1C1=CC(Cl)=CC(Cl)=C1 TXEIIPDJKFWEEC-UHFFFAOYSA-N 0.000 description 2
- 229960001353 tafamidis Drugs 0.000 description 2
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 206010019889 Hereditary neuropathic amyloidosis Diseases 0.000 description 1
- 208000005531 Immunoglobulin Light-chain Amyloidosis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010036105 Polyneuropathy Diseases 0.000 description 1
- 206010064930 age-related macular degeneration Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 208000022368 idiopathic cardiomyopathy Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000007824 polyneuropathy Effects 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 201000007905 transthyretin amyloidosis Diseases 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361762750P | 2013-02-08 | 2013-02-08 | |
| US61/762,750 | 2013-02-08 | ||
| US201361863818P | 2013-08-08 | 2013-08-08 | |
| US61/863,818 | 2013-08-08 | ||
| PCT/US2014/015421 WO2014124334A2 (en) | 2013-02-08 | 2014-02-07 | Transthyretin antibodies and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016514091A JP2016514091A (ja) | 2016-05-19 |
| JP2016514091A5 true JP2016514091A5 (enExample) | 2017-03-02 |
Family
ID=51300272
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015557148A Pending JP2016514091A (ja) | 2013-02-08 | 2014-02-07 | トランスサイレチン抗体およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US9790269B2 (enExample) |
| EP (1) | EP2953970A4 (enExample) |
| JP (1) | JP2016514091A (enExample) |
| WO (1) | WO2014124334A2 (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160168235A1 (en) * | 2013-07-19 | 2016-06-16 | Board Of Regents Of The University Of Texas System | Transthyretin amyloid-selective and polyreactive catabodies |
| WO2015092077A1 (en) | 2013-12-20 | 2015-06-25 | Neurimmune Holding Ag | Antibody-based therapy of transthyretin (ttr) amyloidosis and human-derived antibodies therefor |
| KR102240417B1 (ko) | 2014-01-29 | 2021-04-13 | 케이엠 바이올로직스 가부시키가이샤 | 항-트랜스티레틴 인간 항체 |
| CN106574258B (zh) * | 2014-01-29 | 2021-03-30 | Km生物医药股份公司 | 抗-运甲状腺素蛋白人源化抗体 |
| TWI781507B (zh) * | 2015-01-28 | 2022-10-21 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| US10633433B2 (en) | 2015-01-28 | 2020-04-28 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US10464999B2 (en) | 2015-01-28 | 2019-11-05 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| US9879080B2 (en) | 2015-01-28 | 2018-01-30 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| TWI718122B (zh) * | 2015-01-28 | 2021-02-11 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| TWI711631B (zh) * | 2015-01-28 | 2020-12-01 | 愛爾蘭商普羅佘納生物科技有限公司 | 抗甲狀腺素運送蛋白抗體 |
| JP7016470B2 (ja) * | 2016-07-02 | 2022-02-07 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| EP3478714A2 (en) * | 2016-07-02 | 2019-05-08 | Prothena Biosciences Limited | Anti-transthyretin antibodies |
| JP7017013B2 (ja) * | 2016-07-02 | 2022-02-08 | プロセナ バイオサイエンシーズ リミテッド | 抗トランスサイレチン抗体 |
| CN116600392A (zh) * | 2016-09-10 | 2023-08-15 | Lg电子株式会社 | 执行副链路操作的方法和用户设备以及控制该设备的设备 |
| EP3515482A4 (en) | 2016-09-19 | 2020-09-30 | The Wistar Institute Of Anatomy And Biology | ASSOCIATION OF NEW ZIKA VIRUS VACCINES AND ANTI-DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST ZIKA VIRUS |
| PE20210042A1 (es) * | 2017-10-06 | 2021-01-08 | Prothena Biosciences Ltd | Metodos para detectar transtiretina |
| CN111315213B (zh) * | 2017-10-06 | 2023-09-12 | 普罗塞纳生物科学有限公司 | 抗甲状腺素运载蛋白抗体 |
| AU2018375356A1 (en) | 2017-11-29 | 2020-05-14 | Neotope Neuroscience Limited | Lyophilized formulation of a monoclonal antibody against transthyretin |
| WO2019241497A1 (en) * | 2018-06-13 | 2019-12-19 | The Wistar Institute Of Anatomy And Biology | Dna antibody constructs for use against zika virus |
| US20210400932A1 (en) | 2018-11-09 | 2021-12-30 | Neurimmune Ag | Patient-derived amyloid xenograft non-human animal model |
| JP7360142B2 (ja) * | 2019-05-21 | 2023-10-12 | 国立大学法人 熊本大学 | アミロイドーシス治療薬の新規スクリーニング方法 |
| US20220241247A1 (en) * | 2019-05-31 | 2022-08-04 | Plex Pharmaceuticals, Inc. | Pharmacological agents for treating protein aggregation diseases of the eye |
| EP3988122A4 (en) * | 2019-12-17 | 2023-01-18 | Yizhou (Shanghai) Biological Medicine Co, Ltd. | USE OF TRANSTHYRETIN FOR INTRODUCTION TO THE EYE AND MAKING DROPS |
| US11998237B2 (en) | 2020-06-03 | 2024-06-04 | Bard Access Systems, Inc. | Intraosseous device including a sensing obturator |
| CN114098918B (zh) | 2020-08-25 | 2025-12-12 | 巴德阿克塞斯系统股份有限公司 | 成角度的骨内进入系统 |
| EP4203821B1 (en) | 2020-09-01 | 2025-10-29 | Bard Access Systems, Inc. | Retractable intraosseous access system |
| CN215839325U (zh) * | 2020-09-09 | 2022-02-18 | 巴德阿克塞斯系统股份有限公司 | 用于骨内进入系统的抽吸设备 |
| CN117062527A (zh) | 2021-01-19 | 2023-11-14 | 埃里莫斯制药有限责任公司 | 作为冠状病毒抗病毒剂的Terameprocol和去甲二氢愈创木酸（NDGA）衍生物 |
| CN114903553A (zh) | 2021-02-08 | 2022-08-16 | 巴德阿克塞斯系统股份有限公司 | 骨内进入系统和用于钻入穿过骨骼的方法 |
| CN117916599A (zh) | 2021-09-07 | 2024-04-19 | 美国西门子医学诊断股份有限公司 | 生物标记物组合物及其使用方法 |
| WO2023099788A1 (en) | 2021-12-03 | 2023-06-08 | Neurimmune Ag | Novel potency assay for antibody-based drugs and useful means therefor |
| EP4296279A1 (en) * | 2022-06-23 | 2023-12-27 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti-transthyretin (ttr) binding proteins and uses thereof |
| JP2025540181A (ja) | 2022-12-05 | 2025-12-11 | ニューリミューン アーゲー | 環状化合物及び抗体を検出するためのアッセイにおけるその使用 |
| CN116396392B (zh) * | 2023-01-17 | 2023-10-27 | 珠海重链生物科技有限公司 | 一种特异性针对异羟基洋地黄毒甙元的抗体及其相关应用 |
| SE2350342A1 (en) * | 2023-03-27 | 2024-09-28 | Anders Olofsson | Composition for use in prevention and/or treatment of human transthyretin amyloidosis |
| EP4713354A1 (en) * | 2023-05-19 | 2026-03-25 | Neurimmune AG | Novel immunotherapy for musculoskeletal disorders and conditions |
| CN121646476A (zh) | 2023-06-07 | 2026-03-10 | 神经免疫有限公司 | 用于治疗淀粉样变性的疫苗 |
| TW202528347A (zh) | 2023-11-15 | 2025-07-16 | 瑞士商紐立慕公司 | 抗運甲狀腺素蛋白抗體、包含所述抗體之組成物及用於治療或預防運甲狀腺素蛋白介導之澱粉樣變性的方法 |
Family Cites Families (64)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5156965A (en) | 1983-11-29 | 1992-10-20 | Igen, Inc. | Catalytic antibodies |
| FR2562421B1 (fr) | 1984-04-09 | 1989-02-17 | Sandoz Sa | Perfectionnements a la therapie par l'interleukine |
| US4975282A (en) | 1985-06-26 | 1990-12-04 | The Liposome Company, Inc. | Multilamellar liposomes having improved trapping efficiencies |
| ES2039203T3 (es) | 1985-11-22 | 1993-09-16 | Takeda Chemical Industries, Ltd. | Composicion de liposomas. |
| JP2666345B2 (ja) | 1987-04-16 | 1997-10-22 | 武田薬品工業株式会社 | リポソーム製剤およびその製造法 |
| US5273876A (en) | 1987-06-26 | 1993-12-28 | Syntro Corporation | Recombinant human cytomegalovirus containing foreign gene |
| EP0448650A4 (en) | 1989-02-01 | 1992-05-13 | The General Hospital Corporation | Herpes simplex virus type i expression vector |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| US5658753A (en) | 1989-04-25 | 1997-08-19 | Paul; Sudhir | Catalytic antibody components |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
| WO1992005266A2 (en) | 1990-09-21 | 1992-04-02 | Viagene, Inc. | Packaging cells |
| DE69131908T3 (de) | 1991-02-19 | 2008-04-03 | Oxford Biomedica (Uk) Ltd. | Viruspartikel mit veraendertem wirtspektrum |
| GB9105383D0 (en) | 1991-03-14 | 1991-05-01 | Immunology Ltd | An immunotherapeutic for cervical cancer |
| US5412087A (en) | 1992-04-24 | 1995-05-02 | Affymax Technologies N.V. | Spatially-addressable immobilization of oligonucleotides and other biological polymers on surfaces |
| WO1993019660A1 (en) | 1992-04-03 | 1993-10-14 | Baylor College Of Medicine | Gene therapy using the intestine |
| AU6014094A (en) | 1992-12-02 | 1994-06-22 | Baylor College Of Medicine | Episomal vectors for gene therapy |
| JPH09510601A (ja) | 1993-11-12 | 1997-10-28 | ケース・ウエスタン・リザーブ・ユニバーシティ | ヒト遺伝子治療用のエピソーム発現ベクター |
| US5928944A (en) | 1994-02-04 | 1999-07-27 | The United States Of America As Represented By The Department Of Health And Human Services | Method of adenoviral-medicated cell transfection |
| US5731172A (en) | 1994-03-09 | 1998-03-24 | Sumitomo Pharmaceuticals Company, Ltd. | Recombinant adenovirus and process for producing the same |
| US5604090A (en) | 1994-06-06 | 1997-02-18 | Fred Hutchinson Cancer Research Center | Method for increasing transduction of cells by adeno-associated virus vectors |
| US5693508A (en) | 1994-11-08 | 1997-12-02 | Chang; Lung-Ji | Retroviral expression vectors containing MoMLV/CMV-IE/HIV-TAR chimeric long terminal repeats |
| JP3770333B2 (ja) | 1995-03-15 | 2006-04-26 | 大日本住友製薬株式会社 | 組換えｄｎａウイルスおよびその製造方法 |
| US6110456A (en) | 1995-06-07 | 2000-08-29 | Yale University | Oral delivery or adeno-associated viral vectors |
| US5695937A (en) | 1995-09-12 | 1997-12-09 | The Johns Hopkins University School Of Medicine | Method for serial analysis of gene expression |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| WO1997026919A2 (en) | 1996-01-24 | 1997-07-31 | Warner-Lambert Company | Method of imaging amyloid deposits |
| US5861397A (en) | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
| US6472436B1 (en) | 2000-07-17 | 2002-10-29 | The Salk Institute For Biological Studies | Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production |
| US7311893B2 (en) | 2000-07-25 | 2007-12-25 | Neurochem (International) Limited | Amyloid targeting imaging agents and uses thereof |
| WO2002028441A2 (en) | 2000-10-04 | 2002-04-11 | California Institute Of Technology | Magnetic resonance imaging agents for in vivo labeling and detection of amyloid deposits |
| ES2274973T3 (es) | 2001-04-23 | 2007-06-01 | The Trustees Of The University Of Pennsylvania | Inhibidores de la agregacion de placas amiloides y agentes de obtencion de imagenes diagnosticas. |
| EP1414491A4 (en) | 2001-07-09 | 2005-07-06 | Elan Pharm Inc | METHOD OF INHIBITING THE TOXICITY OF AMYLOID |
| US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| ATE405840T1 (de) | 2002-12-19 | 2008-09-15 | Scripps Research Inst | Zusammensetzungen und verfahren zur stabilisierung von transthyretin und zur hemmung von transthyretin-fehlfaltung |
| CA2512647C (en) | 2003-01-07 | 2013-10-08 | Symphogen A/S | Method for manufacturing recombinant polyclonal proteins |
| US20060035946A1 (en) | 2003-01-22 | 2006-02-16 | The General Hospital Corporation | Amyloid-binding, metal-chelating agents |
| GB0313386D0 (en) | 2003-06-10 | 2003-07-16 | Univ London | Treatment of disease |
| US20060079578A1 (en) | 2003-06-23 | 2006-04-13 | Julie Laurin | Pharmaceutical formulations of amyloid inhibiting compounds |
| TWI333977B (en) | 2003-09-18 | 2010-12-01 | Symphogen As | Method for linking sequences of interest |
| US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
| JP2007538103A (ja) | 2004-05-20 | 2007-12-27 | ザ スクリップス リサーチ インスティテュート | トランスサイレチン安定化 |
| PL1787126T3 (pl) | 2004-07-20 | 2010-03-31 | Symphogen As | Sposób charakteryzowania poliklonalnej linii komórkowej |
| CN101072555B (zh) | 2004-12-08 | 2011-06-29 | 矫正诊疗公司 | 治疗与视黄醇有关的疾病的方法、分析和组合物 |
| US20070111258A1 (en) | 2005-06-22 | 2007-05-17 | Kaufman Randal J | Compositions and methods for modulating the acute phase response |
| WO2007022138A2 (en) | 2005-08-11 | 2007-02-22 | The Scripps Research Institute | Genistein inhibition of transthyretin amyloidosis |
| US7700616B2 (en) | 2006-05-08 | 2010-04-20 | Molecular Neuroimaging, Llc. | Compounds and amyloid probes thereof for therapeutic and imaging uses |
| CA2668640A1 (en) * | 2006-11-01 | 2008-05-29 | George Mason Intellectual Properties, Inc. | Biomarkers for neurological conditions |
| WO2008141074A1 (en) | 2007-05-10 | 2008-11-20 | Salk Institute For Biological Studies | Identification of compounds that protect against amyloid diseases |
| HRP20100640T1 (hr) | 2007-05-25 | 2010-12-31 | Symphogen A/S | Postupak proizvodnje rekombinantnog poliklonskog proteina |
| US20090123373A1 (en) | 2007-11-05 | 2009-05-14 | Yanming Wang | Amyloid-imaging agents |
| RU2476886C2 (ru) | 2007-11-22 | 2013-02-27 | Симфоген А/С | Способ характеризации рекомбинантного поликлонального белка |
| WO2010030203A1 (en) | 2008-09-09 | 2010-03-18 | Biocodex - Incubação De Empresas De Ciências Da Vida, S.A. | Monoclonal antibody to human amyloidogenic and modified forms of transthyretin and its use in the detection and treatment of fap and pathologies presenting modified ttr |
| US20100233176A1 (en) * | 2008-10-06 | 2010-09-16 | Cashman Neil R | Methods and systems for predicting misfolded protein epitopes |
| EP2352744B1 (en) | 2008-10-15 | 2016-09-21 | Somagenics, Inc. | Short hairpin rnas for inhibition of gene expression |
| AU2009307677C1 (en) | 2008-10-20 | 2022-09-22 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of transthyretin |
| WO2010083328A2 (en) | 2009-01-14 | 2010-07-22 | The Salk Institute For Biological Studies | Methods for screening and compounds that protect against amyloid diseases |
| JP2010195710A (ja) | 2009-02-25 | 2010-09-09 | Kumamoto Univ | アミロイド線維形成抑制剤及びその利用 |
| US9101643B2 (en) | 2009-11-03 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR) |
| US20130203083A1 (en) * | 2010-02-10 | 2013-08-08 | Trustees Of Boston University | Serum clusterin levels in systemic amyloidosis featuring cardiomyopathy |
| CA2792291A1 (en) | 2010-03-29 | 2011-10-06 | Kumamoto University | Sirna therapy for transthyretin (ttr) related ocular amyloidosis |
| WO2011140333A1 (en) | 2010-05-07 | 2011-11-10 | The Board Of Trustees Of The Leland Stanford Junior University | Identification of stabilizers of multimeric proteins |
| US9534048B2 (en) * | 2012-08-24 | 2017-01-03 | University Health Network | Antibodies to TTR and methods of use |
-
2014
- 2014-02-07 EP EP14749029.6A patent/EP2953970A4/en not_active Withdrawn
- 2014-02-07 US US14/760,194 patent/US9790269B2/en active Active
- 2014-02-07 WO PCT/US2014/015421 patent/WO2014124334A2/en not_active Ceased
- 2014-02-07 JP JP2015557148A patent/JP2016514091A/ja active Pending
-
2017
- 2017-09-26 US US15/716,154 patent/US20180022797A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Caine et al. | Borrelia burgdorferi outer surface protein C (O sp C) binds complement component C 4b and confers bloodstream survival | |
| Hoskin et al. | Tau immunotherapies for Alzheimer’s disease | |
| Sellers et al. | The hidden burden of influenza: a review of the extra‐pulmonary complications of influenza infection | |
| Lannfelt et al. | Perspectives on future Alzheimer therapies: amyloid-β protofibrils-a new target for immunotherapy with BAN2401 in Alzheimer’s disease | |
| Imbimbo et al. | Solanezumab for the treatment of mild-to-moderate Alzheimer’s disease | |
| Bustamante et al. | A full-length recombinant Plasmodium falciparum PfRH5 protein induces inhibitory antibodies that are effective across common PfRH5 genetic variants | |
| Kontsekova et al. | Identification of structural determinants on tau protein essential for its pathological function: novel therapeutic target for tau immunotherapy in Alzheimer’s disease | |
| Pauly et al. | A novel antibody against human properdin inhibits the alternative complement system and specifically detects properdin from blood samples | |
| US9216217B2 (en) | Oligomer-specific amyloid beta epitope and antibodies | |
| US9534048B2 (en) | Antibodies to TTR and methods of use | |
| Yang et al. | Transthyretin as both a sensor and a scavenger of β-amyloid oligomers | |
| Gresa-Arribas et al. | Diagnosis and significance of antibody titers in anti-NMDA receptor encephalitis, a retrospective study | |
| Efthymiou et al. | Anti-hsp60 antibody responses based on Helicobacter pylori in patients with multiple sclerosis:(ir) Relevance to disease pathogenesis | |
| ES2955992T3 (es) | Método para evaluar una sinucleinopatía | |
| WO2011100637A1 (en) | Markers for determination of patient responsiveness | |
| JP7732015B2 (ja) | アルファ－シヌクレインアッセイ | |
| JP2014533357A (ja) | 脳における高レベルのα−シヌクレインを診断するための抗α−シヌクレイン抗体の使用 | |
| EP3837286A1 (en) | Antibodies to human znt8 | |
| Filli et al. | Predicting responsiveness to fampridine in gait‐impaired patients with multiple sclerosis | |
| JP2017538412A5 (enExample) | ||
| Goñi et al. | Production of monoclonal antibodies to pathologic β-sheet oligomeric conformers in neurodegenerative diseases | |
| JP7258762B2 (ja) | 新規アミロイドベータオリゴマー特異的結合分子 | |
| Cruz et al. | Proteostasis as a fundamental principle of Tau immunotherapy | |
| Chatzimichail et al. | Ranibizumab biosimilars in treating retinal disorders: a cost-effective revolution? | |
| Rispens et al. | Cross-reactivity of antibodies to rituximab with other therapeutic anti-CD20 antibodies |